| Project/Area Number |
19790776
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Toho University (2008-2009)
Tokyo Medical and Dental University (2007) |
|---|
Principal Investigator |
HIGUCHI Tetsuya Toho University, 医学部, 准教授 (00334425)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,440,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥540,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | 薬疹 / CD40リガンド / CD154 / フローサイトメトリー / CD40 / 皮膚診断学 |
|---|
| Research Abstract |
Upregulation of CD40 ligand, an activated T cell marker, was evaluated to be used as a diagnostic method of causative drug for patients with drug eruption. For patients clinically diagnosed as drug eruption, detection of CD40 ligand on peripheral blood mononuclear was compared with the results of conventional drug tests, such as patch test, lymphocyte transforming test and provocation test. In about two third of patients, whose causative drug was confirmed, CD40 ligand detection test was positive, and this method was suggested to be used clinically.
|
